Anti-CancerDrugs 2014.ppt
-
Upload
asudapurmu -
Category
Documents
-
view
219 -
download
0
Transcript of Anti-CancerDrugs 2014.ppt
-
8/11/2019 Anti-CancerDrugs 2014.ppt
1/72
-
8/11/2019 Anti-CancerDrugs 2014.ppt
2/72
Overview
Introduction
Malignant disease accounts for a high proportionof deaths.
The treatment of anticancer drug is to give
palliation, induce remission and, if possible, cure.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
3/72
Overview
Introduction Cancer occurs after normal cells have been
transformed into neoplastic cells through alteration oftheir genetic material and the abnormal expression ofcertain genes.
Neoplastic cells usually exhibit chromosomal
abnormalities and the loss of their differentiatedproperties. These changes lead to uncontrolled celldivision and many result in the invasion of previouslyunaffected organs, a process called metastasis.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
4/72
Advances in Cancer Chemotherapy
Treatment options of cancer:
Surgery: before 1955
Radiotherapy: 1955~1965
Chemotherapy: after 1965
Immunotherapy and Gene therapy
-
8/11/2019 Anti-CancerDrugs 2014.ppt
5/72
Advances in Cancer Chemotherapy
The treatment of a patient with cancer mayaim to:
give palliation, for example prompt relief ofunpleasant symptoms such as superior vena cavaobstruction from a mediastinal tumor
induce remission so that all macroscopic and
microscopic features of the cancer disappear,though disease is known to persist cure, for which all the cells of the clone must be
destroyed.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
6/72
Cancer Chemotherapy
Disease Name 5 Years Survival Rate
Childhood Acute Lymphoblastic Leukemia 50~80%
Adult Acute Lymphoblastic Leukemia 20~60% Childhood Acute Myeloblastic Leukemia 20~60%
Adult Acute Myeloblastic Leukemia 10~20%
Breast Cancer
Premenopausal
10~20% Breast CancerPostmenopausal 0~15%
Hodgkins lymphoma * 40~80%
-
8/11/2019 Anti-CancerDrugs 2014.ppt
7/72
Cancer Chemotherapy
Disease Name 5 Years Survival Rate
Small Cell Lung Cancer Limited Stage
10~20% Extensive Stage 0~5%
Non-Hodgkins lymphoma * 40~65% Ovarian Cancer 40~60% Children Solid Tumor (Nephroblastoma, Rhabdomyosarcoma,
Lymphoma
Osteosarcoma
* 60~90% Trophoblastoma Chorion Epithelioma** 80~90%
Seminoma of Testis** 60~90% Embryonic Carcinoma of Testis 60~80%
Note* Combination with other therapeutics**Chemotherapy Level is high
-
8/11/2019 Anti-CancerDrugs 2014.ppt
8/72
The Classification of
Anticancer Drugs According to chemical structure and
resource of the drug; According to biochemistry mechanisms of
anticancer action;
According to the cycle or phasespecificity of the drug
-
8/11/2019 Anti-CancerDrugs 2014.ppt
9/72
The Classification of
Anticancer Drugs According to chemical structure and
resource of the drug:
Alkylating Agents, Antimetabolite,
Antibiotics, Plant ExtractsHormones
Others.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
10/72
The Classification of
Anticancer DrugsAccording to biochemistry mechanisms of anticancer
action:
Block nucleic acid biosynthesis
Direct influence the structure and function ofDNA
Interfere transcription and block RNA synthesis Interfere protein synthesis and function
Influence hormone homeostasis
Others
-
8/11/2019 Anti-CancerDrugs 2014.ppt
11/72
The Classification of
Anticancer Drugs According to the cycle or phase
specificity of the drug:
Cell cycle nonspecific agents (CCNSA)
Cell cycle specific agents (CCSA)
-
8/11/2019 Anti-CancerDrugs 2014.ppt
12/72
The Basic Concept of
Cell Generation Cycle The cycle of cell replication includes:
MMitosisphase
G1Gap1, period before Sphase
SDNA synthesisphase
G2Gap2,period after Sphase
Growth Fraction (GF
-
8/11/2019 Anti-CancerDrugs 2014.ppt
13/72
-
8/11/2019 Anti-CancerDrugs 2014.ppt
14/72
Growth Fraction (GF)
GFProliferating cell group
Total tumor cell group
CCNSAdrugs that are active
throughout the cell cycle.
CCSA:drugs that act during a specific
phase of the cell cycle.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
15/72
CCSA and CCNSA
Cell Cycle Nonspecific Agents (CCNSA)
drugs that are active throughout the cell
cycle
Alkylating Agents
Platinum Compounds
Antibiotics
-
8/11/2019 Anti-CancerDrugs 2014.ppt
16/72
Cell Cycle Specific Agents (CCSA)drugs that act during a specific phase of
the cell cycleS Phase Specific Drug:
Antimetabolites, Topoisomerase InhabitorsM Phase Specific Drug:
Vinca Alkaloids, TaxanesG2 Phase Specific Drug:
Bleomycin
CCSA and CCNSA
-
8/11/2019 Anti-CancerDrugs 2014.ppt
17/72
Mechanism of Anticancer Drugs
Block nucleic acid (DNA, RNA) biosynthesis
Directly destroy DNA and inhibit DNAreproduction
Interfere transcription and block RNA synthesis
Interfere protein synthesis and function
Influence hormone homeostasis
-
8/11/2019 Anti-CancerDrugs 2014.ppt
18/72
Block Nucleic Acid (DNA, RNA)
BiosynthesisAntimetabolites:
Folic Acid Antagonist:inhibit dihydrofolate
reductase (methotrexate) Pyrimidine Antagonist:inhibit thymidylate
synthetase (fluorouracil); inhibit DNA
polymerase (cytarabine)
Purine Antagonist:inhibit interconversion of
purine nucleotide (mercaptopurine)
Ribonucleoside Diphosphate Reductase Antagonist:
(hydroxyurea)
-
8/11/2019 Anti-CancerDrugs 2014.ppt
19/72
-
8/11/2019 Anti-CancerDrugs 2014.ppt
20/72
Interfere Transcription and
Block RNA Synthesis
Bind with DNA to block RNA production.
doxorubicin
-
8/11/2019 Anti-CancerDrugs 2014.ppt
21/72
Influence the Structure and
Function of DNA
Alkylating Agent:mechlorethamine,cyclophosphamideand thiotepa
Platinum:cis-platinium
Antibiotic:bleomycin and mitomycin C
Topoispmerase inhibitor:camptothecineand podophyllotoxin
-
8/11/2019 Anti-CancerDrugs 2014.ppt
22/72
Influence Hormone Homeostasis
These drugs bind to hormone receptors to blockthe actions of the sex hormones which results in
inhibition of tumor growth. Estrogens and estrogen antagonistic drug Androgens and androgen antagonistic drug Progestogen drug
Glucocorticoid drug Gonadotropin-releasing hormone inhibitor:leuprolide, goserelin
Aromatase inhibitor:aminoglutethimide,anastrazole
-
8/11/2019 Anti-CancerDrugs 2014.ppt
23/72
Anticancer Drugs
Alkylating Agent Antimetabolite
Antibiotics
Alkaloid Hormones
Otherscis-platinumcarboplatinlobaplatin
-
8/11/2019 Anti-CancerDrugs 2014.ppt
24/72
Alkylating Agents
One of the frightening developments of World
War I was the introduction of chemical warfare.
These compounds were known as the nitrogenmustard gases. The nitrogen mustards were
observed to inhibit cell growth, especially of
bone marrow. Shortly after the war, thesecompounds were investigated and shown to inhibit
the growth of cancer cells.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
25/72
Alkylating Agents
Mechanism of Action
Nitrogen mustards inhibit cell reproduction by
binding irreversibly with the nucleic acids (DNA).The specific type of chemical bonding involved is
alkylation. After alkylation, DNA is unable to
replicate and therefore can no longer synthesize
proteins and other essential cell metabolites.Consequently, cell reproduction is inhibited and
the cell eventually dies from the inability to
maintain its metabolic functions.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
26/72
Classification of Alkylating Agents
Bis Chloroethyl Amines
Cyclophosphamide, Chlormethine,
Chlorambucil, Sarcolysine NithrosoureasCarmustineLomustine
Ethyeneammonium or Aziridines
Thiotepatriethylene melamine AlkysulfonatesBusulfan
-
8/11/2019 Anti-CancerDrugs 2014.ppt
27/72
Resistance of Alkylating Agents
Resistance to alkylating agents has severalcauses:
Membrane transport may be decreased. The drug may be bound by glutathione (GSH)
via GSH-S-transferase or metallothioneins
in the cytoplasm and inactivated. The drug may be metabolized to inactive
species.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
28/72
Adverse Effects of Alkylating Agents
Myelosuppression is the dose-limitingadverse effect for alkylating agents.
Nausea and vomiting are common as areteratogenesis and gonadal atrophy,although in the latter cases these are
variable, according to the drug, itsschedule, and route of administration.
Treatment also carries a major risk of
leukemogenesis and carcinogenesis.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
29/72
Alkylating AgentsMustine
Mustine must be injected intravenouslybecause it is highly reactive. It
disappears very rapidly from the blood,the activity of Mustine lasts only a fewminutes.
The main indication for Mustine is intreatment of Hodgkins disease andlymphomas, but it may also be useful inother malignancies.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
30/72
Alkylating Agents
CyclophosphamideCyclophosphamide can also be given orally.Indications
It is used in the treatment of chronic lymphocycticleukemia, non-Hodgkins lymphomas, breast andovarian cancer, and a variety of other cancers.
It is also a potent immunosuppressant, it is used inthe management of rheumatoid disorders and
autoimmune nephritis.Adverse Effects: Alopecia, nausea, vomiting, myelosuppression, and
hemorrhagic cystitis.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
31/72
Alkylating AgentsNitrosoureas
Carmustine, Lomustine, Semustine
Pharmacokinetics:
Nitrosoureas are highly lipophilic andreach cerebrospinal fluid concentrationsthat are about 30% of plasmaconcentrations.
Indications:
Because of their excellent CNSpenetration, carmustine and lomustine
have been used to treat brain tumors.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
32/72
Alkylating Agents
Phenylalanine Nitrogen Mustard
Melphalan is a nitrogen mustard that is
primarily used to treat multiple myeloma(plasma cell myeloma), breast cancer, and
ovarian cancer.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
33/72
Alkylating AgentsAlkysulfonates
Busulfan [Myleran]Indications:
Busulfan is administered orally to treat chroicgranulocytic leukemia and othermyeloproliferative disorders.
Adverse Effects:
Busulfan produces advers effects related tomyelosuppression. It only occasionally producesnausea and vomitting. In high doses, it producesa rare but sometimes fatal pulmonaryfibrosis, busulfan lung.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
34/72
Alkylating AgentsThiotepa
Thiotepa is converted rapidly by liver
mixed-function oxidases to its activemetabolite triethylenephosphoramide
(TEPA); it is active in bladder cancer.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
35/72
Antimetabolites
General Characteristics
Antimetabolites are S phase-specific
drugs that are structural analogues of
essential metabolites and that interfere
with DNA synthesis.Myelosuppression is the dose-limiting
toxicity for all drugs in this class.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
36/72
Classification of Antimetabolites
Folic acidAntagonists: MTX
Purine Antagonists: 6MP
6TG
Pyrimidine Antagonists5FU
araC
HU
-
8/11/2019 Anti-CancerDrugs 2014.ppt
37/72
AntimetabolitesFolic Acid Antagonist
Methotrexate MTX
Mechanism of Action
The structures of MTX and folic acid are
similar. MTX is actively transported into
mammalian cells and inhibits dihydrofolate
reductase, the enzyme that normally convertsdietary folate to the tetrahydrofolate form
required for thymidine and purine synthesis.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
38/72
Antimetabolites
Folic Acid AntagonistMethotrexate MTX
Indications
The use of MTX in the treatment ofchoriocarinoma, a trophoblastic tumor, was the
first demonstration of curative chemotherapy.
It is especially effective for treating acutelymphocytic leukemia and for treating the
meningeal metastases of a wide range of tumors.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
39/72
Antimetabolites
Folic Acid Antagonist
Methotrexate MTXAdverse Effects
MTX is myelosuppressive, producing severeleukopenia, bone marrow aplasia, andthrombocytopenia.
This agent may produce severe gastrointestinal
disturbances. Renal toxicity may occur because of precipitation
(crystalluria) of the 7-OH metabolite of MTX.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
40/72
Antimetabolites
Purine Antagonists
6-Mercapapurine6-MPThe drugs are believed to act similarly to inhibitpurine base synthesis, although their exact
mechanisms of action are still uncertain.Indications: Mercaptopurine is used primarily for the maintenance
of remission in patients with acute lymphocyticleukemia and is given in combination with MTX for
this purpose.Adverse Effects: Well tolerate. Myelosuppression is generally mild with
thioguanine.Long-term mercaptopurine use may cause
hepatotoxicity.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
41/72
Antimetabolites
Pyrimidine Antagonists5-Fluorouracil (5-FU)
Mechanism of Action
Fluorouracil is an analogue of thymine in which the
methyl group is replaced by a fluorine atom. It has
two active metabolites: 5-FdUMP and 5-FdUTP. 5-
FdUMP inhibits thymidylate synthetases and preventsthe synthesis of thymidine, a major building block of
DNA. 5-FdUTP is incorporated into RNA by RNA
polymerase and interferes with RNA function.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
42/72
Antimetabolites
Pyrimidine Antagonists5-Fluorouracil (5-FU)
Indications
Fluorouracil is exclusively used to treat
solid tumors, especially breast, colorectal,
and gastric tumors and squamous celltumors of the head and neck.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
43/72
Antimetabolites
Pyrimidine Antagonists5-Fluorouracil (5-FU)Adverse Effects
Fluorouracil may cause nausea and vomiting,myelosuppression, and oral and gastrointestinalulceration. Nausea and vomitting are usually mild.
With fluorouracil, myelosuppression is more
problematic after bolus injections, whereasmucosal damage is dose-limiting with continuousinfusions.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
44/72
AntimetabolitesPyrimidine Antagonists
CytarabineIndications
Cytarabine has a narrow clinical spectrum and isprimarily used in combination with daunorubicin orthioguanine for the treatment of acutenonlymphocytic leukemia.
Adverse Effects: High doses of cytarabine can damage the liver,
heart, and other organs.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
45/72
Antibiotics
Classification of Antibiotics: Adriamycin (Anthracyaline Antibiotics)
Mitomycin C
Bleomycin
Actinomycin D
-
8/11/2019 Anti-CancerDrugs 2014.ppt
46/72
Antibiotics
Adriamycin and Daunorubicin Properties:
Adriamycin and Daunorubicin are tetracycline ringswith the sugar daunosamine. They are DNAintercalating agents that block the synthesis of DNAand RNA.
These agents are primarily toxic during the S phaseof cell cycle.
These agents imparts a red tinge to the urine.
Adramycin is used to treat acute leukemias, lymphoma,
and a number of solid tumors.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
47/72
Antibiotics
Mitomycin C:Mechanism: Mitomycin C is an antineoplastic antibiotic that
alkylates DNA and thereby causes strandbreakage and inhibition of DNA synthesis.Indications: It is primarily used in combination with
vinvristine as salvage therapy for breast cancer.Adverse Effects: Mitomycin produces delays and prolonged
myelosuppression that preferentially affectsplatelets and leukocytes.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
48/72
Antibiotics
Actinomycin D: Actinomycin D intercalates DNA and thereby
prevents DNA transcription and messenger RNAsynthesis.
The drug is given intravenously, and its clinicaluse is limited to the treatment of trophoblastic
(gestational) tumors and the treatment ofpediatric tumors, such as Wilms tumor andEwings sarcoma.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
49/72
Antibiotics
Bleomycin:Mechanism: The drug has its greatest effect on neoplastic cell in
the G2 phase of the cell replication cycle.Althoughbleomycin intercalates DNA, the major cytotoxicity isbelieved to result from ironcatalyzed free radicalformation and DNA strand breakage.
Indications: It is useful in Hodgkins and non-Hodgkins lymphomas,
testicular cancer, and several other solid tumors.Adverse Effects: Bleomycin produces very little myelosuppression. The
most serious toxicities of Bleomycin are pulmonaryand mucocutaneous reactions.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
50/72
Anti-Cancer Plant Allaloids
Tubulin-Binding Agents
Vinca Alkaloids:The cellular mechanism of
action of vinca alkaloids is the prevention of
microtubule assembly, causing cells to arrest
in the late G2 phase by preventing formationof mitotic filaments for nuclear and cell
division.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
51/72
Anti-Cancer Plant Allaloids
Tubulin-Binding Agents
Vinca alkaloids:
Vinblastine,vincristin, vindesine and vinorelbine are allalkaloids derived from the periwinkle plant (Vinca rosea).
Indications:
Vinblastine is used in combination with Bleomycin
and Cisplatin for metastatic testicular tumors. Vincristine is used in combination with prednisone
to induce remission in childhood leukemia.
Vinorelbine is used to treat non-small-cell lung
cancer and breast cancer.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
52/72
-
8/11/2019 Anti-CancerDrugs 2014.ppt
53/72
Interfere the Function of Ribosome:
Cephalotaxus Alkaloids :Harringtonine
Homoharringtonine
Anti-Cancer Plant Allaloids
-
8/11/2019 Anti-CancerDrugs 2014.ppt
54/72
Platinum Compound
Cisplatin:Mechanism of Action:
Cisplatin binds to guanine in DNA andRNA, and the interaction is stabilized by
hydrogen bonding. The molecular
mechanism of action is unwinding andshortening of the DNA helix.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
55/72
Platinum Compound
Cisplatin:Indications:
Cisplatin has efficacy against a wide range ofneoplasms. It is given intravenously as a first-line drug for testicular, ovarian, and bladdercancer, and it is also useful in the treatment ofmelanoma and a number of other soild tumors.
Adverse Effect: Cisplatin produces relatively little
myelosuppression but can cause severe nausea,vomiting, and nephrotoxicity.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
56/72
Platinum Compound
Carboplatin:
Indication:
Carboplatin has a similar spectrum ofactivity, but it is approved only as asecond-line drug for ovarian cancer.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
57/72
Hormones
Several types of hormone-dependent cancer(especially breast, prostate, and endometrial
cancer) respond to treatment with theircorresponding hormone antagonists.
Estrogen antagonists are primarily used in thetreatment of breast cancer, whereas androgenantagonists are used in the treatment ofprostate cancer. Corticosteroids are particularlyuseful in treating lymphocytic leukemias andlymphomas.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
58/72
Hormones
Estrogens:
Estrogens inhibit the effects of endogenous
androgens and androgen-dependent metastatic
prostatic carcinoma. Diethylstilbestrol is usually
the agent of choice.
Cardiac and cerebrovascular complications andcarcinoma of the male breast are potential
adverse effects.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
59/72
Hormones
Progenstins:
Progestins are useful in the management of
endometrial carcinoma and back-up therapy for
metastatic hormone-dependent breast cancer.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
60/72
Hormones
Antiestrogen: Tamoxifen Tamoxifen is the drug of choice in
postmenopausal women with or recovering frommetastatic breast cancer. It is most effective inpatients who have estrogen receptor-positivetumors.
Tamoxifen is also used as adjunvctive therapy tooophorectomy to leuprolide or goserelin inpremenopausal women with estrogen receptor-positive tumors.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
61/72
Hormones
Androgens: Androgen activity in breast cancer is similar to
that of estrogens, perhaps for the samemechanistic reasons.
Virilizing effects and hepatic toxicity make themunacceptable to most patients.
Fluoxymesterone is the most widely used agent. Danazol has use in hematology in aplastic anemia
and congenital anemias.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
62/72
Hormones
Glucocorticoids: They are integral components of curative therapy
for acute lymphoblastic leukemia, non-Hodgkinslymphoma, and Hodgkins disease.
Glucocorticoids have essential roles in theprevention of allergic reaction, emesis control,
relief of intracranial hypertension or spinal cordcompression in neurologic complications, and painrelief.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
63/72
-
8/11/2019 Anti-CancerDrugs 2014.ppt
64/72
Drug Resistance
De novo Resistance
Acquired Resistance Multidrug Resistance (MDR)
-
8/11/2019 Anti-CancerDrugs 2014.ppt
65/72
Drug Resistance
De novo resistance:
De novo resistance can be de novo genetic (i.e.
the cells are initially inherently resistant), or canarise because drugs are unable to reach the
target cells because of permeability barriers
such as the blood-brain barrier.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
66/72
Drug Resistance
Acquired Resistance:
Acquired drug resistance may result from
genomic mutations, such as the induction ordeletion of enzymes involved in drug inactivationor drug activation, respectively.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
67/72
-
8/11/2019 Anti-CancerDrugs 2014.ppt
68/72
Drug Toxicity
The most common toxicities of antineoplastic
drugs result from inhibition of cell replication in
the bone marrow, gastrointestinal epithelium, and
hair follicles. Many antineoplastic drugs also
stimulate the chemoreceptor trigger zone in the
medulla and thereby elicit nausea and vomiting.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
69/72
Immunomodulating Drugs
Immunosuppressive Agents:
Act to suppress immune mechanisms and are usedto treat autoimmune diseases or to prevent graft
rejection following tissue transplantation.
Ciclosporin, Tacrolimus, adrenocortical hormones,antimetabolites, alkylating agent, antilymphocyte
globulin, Mycophenolate Mofetil
-
8/11/2019 Anti-CancerDrugs 2014.ppt
70/72
Immunomodulating Drugs
Immunopotentiator:
Enhance antitumor immunity and are used to
treat neoplastic disease.
Recombinant Interferons and Cytokines.
-
8/11/2019 Anti-CancerDrugs 2014.ppt
71/72
Terima kasih!
-
8/11/2019 Anti-CancerDrugs 2014.ppt
72/72